NHS funds mostly spent on chronic conditions, not specialty meds

Pills and vitamins

Pharma players large and small have raged at the U.K. price watchdog NICE over its stinginess in approving costly new specialty meds, particularly cancer treatments, because of concerns over what they will cost England’s National Health Service. But a new reports shows that it's spending on drugs for chronic illnesses like diabetes and depression that are the real budget busters.

The report from the Health and Social Care Information Centre (HSCIC) says that for 9 years running, drugs to treat diabetes were the largest single category of spending, hitting £2.6 million ($3.5 million) a day in 2014. The total amount spent for diabetes drugs was £936.7 million ($1.2 billion) in 2015, up £87.6 million.

The category of drugs that accounted for the largest jump in prescriptions was antidepressants, the report said. The NHS wrote 61 million prescriptions for antidepressants, a jump of 6.8% from the previous year and up 107.6% from a decade ago. In total the NHS wrote 1.08 billion prescriptions, up 1.8% from the previous year. Of those, almost 90% were given free, mostly to patients over the age of 60.  


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Of course, many of the prescriptions in the largest categories would be for generic drugs and this is not where Big Pharma makes its money. And so the battles have been fought over the reluctance of price watchdog NICE to approve drugs like Johnson & Johnson’s chronic lymphocytic leukemia med Imbruvica. Its rejection this year led Mark Hicken, managing director of J&J’s Janssen unit in the U.K., to say that the country was again lagging behind other EU countries that had already approved the treatment.

Just last week, Japan’s Eisai lashed out at the NHS for excluding its thyroid cancer drug Lenvima for coverage by the revamped Cancer Drugs Fund (CDF) and delaying a reconsideration until next year.

Gary Hendler, Eisai EMEA head, told Reuters that the drugmaker was evaluating all its options, including legal action and rethinking its commitment to the U.K. because of the delay for a drug which Eisai actually manufactures there.

- read the announcement

Related Articles:
Look out, drugmakers: NICE is taking the reins of England's Cancer Drugs Fund
NICE invites angry J&J to make a Cancer Drugs Fund case for Imbruvica
Eisai considers legal action over NICE delay of Lenvima


Suggested Articles

Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.